These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 3511396)

  • 1. Risk factors in aluminum toxicity in children with chronic renal failure.
    Santos F; Massie MD; Chan JC
    Nephron; 1986; 42(3):189-95. PubMed ID: 3511396
    [No Abstract]   [Full Text] [Related]  

  • 2. Phosphate binders in hyperphosphatemia of chronic renal failure.
    Wasan SM; Godley PJ
    DICP; 1991 Sep; 25(9):942-5. PubMed ID: 1949972
    [No Abstract]   [Full Text] [Related]  

  • 3. [Phosphate binders for therapy of hyperphosphatemia causing secondary hyperparathyroidism and renal osteodystrophy in patients with chronic renal failure].
    Kanagawa S; Yosikawa Y; Dohi Y
    Nihon Rinsho; 1991 Dec; 49 Suppl():770-4. PubMed ID: 1808348
    [No Abstract]   [Full Text] [Related]  

  • 4. Acute aluminemic encephalopathy in chronic renal failure: the citrate factor.
    Bakir AA
    Int J Artif Organs; 1989 Dec; 12(12):741-3. PubMed ID: 2613353
    [No Abstract]   [Full Text] [Related]  

  • 5. Bone aluminum deposition in maintenance dialysis patients treated with aluminium-free dialysate: role of aluminium hydroxide consumption.
    Heaf JG; Pødenphant J; Andersen JR
    Nephron; 1986; 42(3):210-6. PubMed ID: 3945361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aluminum and phosphate.
    Kaye M; Turner M; Ardila M; Wiegmann T; Hodsman A
    Kidney Int Suppl; 1988 Mar; 24():S172-4. PubMed ID: 3163042
    [No Abstract]   [Full Text] [Related]  

  • 7. Calcium carbonate in hyperphosphatemia.
    Mayo M; Middleton RK
    DICP; 1991 Sep; 25(9):945-7. PubMed ID: 1949973
    [No Abstract]   [Full Text] [Related]  

  • 8. The fatal interplay of aluminum and citrate in chronic renal failure: a lesson from three decades ago.
    Bakir AA
    Artif Organs; 2015 Feb; 39(2):87-9. PubMed ID: 25683287
    [No Abstract]   [Full Text] [Related]  

  • 9. Can low-dosage aluminium hydroxide control the plasma phosphate without bone toxicity?
    Jenkins DA; Gouldesbrough D; Smith GD; Cowie JF; Winney RJ
    Nephrol Dial Transplant; 1989; 4(1):51-6. PubMed ID: 2494599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aluminum loading in children with chronic renal failure.
    Sedman AB; Miller NL; Warady BA; Lum GM; Alfrey AC
    Kidney Int; 1984 Aug; 26(2):201-4. PubMed ID: 6503137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deferoxamine and aluminum removal.
    Swartz RD
    Am J Kidney Dis; 1985 Nov; 6(5):358-64. PubMed ID: 3904429
    [No Abstract]   [Full Text] [Related]  

  • 12. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease.
    Salusky IB; Foley J; Nelson P; Goodman WG
    N Engl J Med; 1991 Feb; 324(8):527-31. PubMed ID: 1992306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hydroxyproline in the dialysate as a parameter of secondary hyperparathyroidism. Effects of phosphate reduction and alkalization].
    Schiessl JH; Schweigart U; Bottermann P; Kopp KF
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1310-3. PubMed ID: 25525
    [No Abstract]   [Full Text] [Related]  

  • 14. Citric acid in calcium effervescent tablets may favour aluminium intoxication.
    Dorhout Mees EJ; Basçi A
    Nephron; 1991; 59(2):322. PubMed ID: 1956499
    [No Abstract]   [Full Text] [Related]  

  • 15. The use of deferoxamine in the management of aluminum accumulation in bone in patients with renal failure.
    Malluche HH; Smith AJ; Abreo K; Faugere MC
    N Engl J Med; 1984 Jul; 311(3):140-4. PubMed ID: 6377067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the impairment of renal function and of the pH of gastric secretion on the efficacy of Al(OH)3 to reduce serum inorganic phosphorus.
    Barsotti G; Lazzeri M; Polloni A; Morelli E; Giovannetti E; Lupetti S; Cupisti A; Dani L; Giovannetti S
    Adv Exp Med Biol; 1986; 208():493-9. PubMed ID: 3565160
    [No Abstract]   [Full Text] [Related]  

  • 17. Prevention and treatment of the abnormalities in divalent ion metabolism in renal failure.
    Massry SG
    Semin Nephrol; 1986 Jun; 6(2):114-21. PubMed ID: 3303238
    [No Abstract]   [Full Text] [Related]  

  • 18. What treatment would you advise for a 1-year-old child with chronic renal failure who has been on aluminum hydroxide as a phosphate binder for 6 months and then develops epilepsy and is found to have a grossly raised plasma aluminum concentration?
    Andreoli SP; Chesney RW; Salusky IB; Sedman AB
    Pediatr Nephrol; 1990 Jul; 4(4):318. PubMed ID: 2206897
    [No Abstract]   [Full Text] [Related]  

  • 19. Osteomalacia and bone disease arising from aluminum.
    Coburn JW; Norris KC; Nebeker HG
    Semin Nephrol; 1986 Mar; 6(1):68-89. PubMed ID: 3110896
    [No Abstract]   [Full Text] [Related]  

  • 20. Aluminum-related osteomalacia in renal-failure patients.
    Vick KE; Johnson CA
    Clin Pharm; 1985; 4(4):434-9. PubMed ID: 3899471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.